Kentarou Kuroishi

Safety and efficacy of mirabegron as ‘add‐on’ therapy in patients with overactive bladder treated with solifenacin: a post‐marketing, open‐label study in Japan ( <scp>MILAI</scp> study)

Osamu Yamaguchi, Hidehiro Κakizaki, Yukio Homma et al. · British Journal of Urology · 2015 · 100 citations · Full text

Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia

Hann‐Chorng Kuo, Kyu‐Sung Lee, Yan-qun Na et al. · Neurourology and Urodynamics · 2014 · 98 citations

Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real‐World Clinical Setting: A<scp>J</scp>apanese Post‐Marketing Study

Yumiko Nozawa, Daisuke Kato, Hiromi Tabuchi et al. · LUTS Lower Urinary Tract Symptoms · 2016 · 28 citations · Full text

Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post‐marketing study

Masaki Yoshida, Yumiko Nozawa, Daisuke Kato et al. · LUTS Lower Urinary Tract Symptoms · 2017 · 19 citations · Full text

Real‐world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post‐marketing study

Takao Katoh, Kana Kuwamoto, Daisuke Kato et al. · International Journal of Urology · 2016 · 18 citations